Across TCGA pan-cancer cohorts, ZNF358 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF358 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZNF358 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZNF358 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ZNF358 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.935	0.700	.009	7	view →
PDAC	OS	Median	III,IV	0.172	1.000	.038	6	view →
LUAD	DFS	Tertile	III,IV	1.000	0.588	.040	2	view →
GBM	DFS	Median	All	0.200	0.319	.043	2	view →
LSCC	OS	Tertile	II,III,IV	0.932	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ZNF358 tumor-vs-normal RNA expression · all ZNF358 data types